{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:48:17Z","timestamp":1791150497042,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T00:00:00Z","timestamp":1339977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Herpes zoster is a common infectious disease that can result in significant acute and chronic morbidity. The safety and efficacy of once\u2010daily oral valomaciclovir (EPB\u2010348) was evaluated for non\u2010inferiority to 3\u2010times daily valacyclovir, an approved therapy. In this study, 373 immunocompetent adults with onset of a herpes zoster rash within the preceding 72\u2009hr were randomly assigned to receive one of four treatments for 7 days: (1) EPB\u2010348 1,000\u2009mg once\u2010daily; (2) EPB\u2010348 2,000\u2009mg once\u2010daily; (3) EPB\u2010348 3,000\u2009mg once\u2010daily; or (4) valacyclovir 1,000\u2009mg 3\u2010times daily. A 20% margin was the reference for non\u2010inferiority assessment. For the primary efficacy measure of time to complete crusting of the zoster rash by Day 28, non\u2010inferiority criteria were met for once\u2010daily EPB\u2010348 2,000\u2009mg and once\u2010daily EPB\u2010348 3,000\u2009mg compared to 3\u2010times daily valacyclovir. Additionally, EPB\u2010348 3,000\u2009mg significantly shortened the time to complete rash crusting by Day 28 compared to valacyclovir. For secondary efficacy measures, non\u2010inferiority was achieved for the EPB\u2010348 1,000 and 2,000\u2009mg groups compared to the valacyclovir group for time to rash resolution by Day 28. No EPB\u2010348 group was non\u2010inferior to valacyclovir for time to cessation of new lesion formation or time to cessation of pain by Day 120, though no significant differences occurred between treatment groups. Nausea, headache, and vomiting were the most common adverse events. Based on these results, additional studies are warranted to define further EPB\u2010348's potential as an effective and safe therapy for acute herpes zoster. J. Med. Virol. 84: 1224\u20131232, 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/jmv.23329","type":"journal-article","created":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T22:28:29Z","timestamp":1340058509000},"page":"1224-1232","source":"Crossref","is-referenced-by-count":31,"title":["Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: A randomized, double\u2010blind, active\u2010controlled trial"],"prefix":"10.1002","volume":"84","author":[{"given":"Stephen K.","family":"Tyring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Plunkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita R.","family":"Scribner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Broker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Herrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lane T.","family":"Handke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Valomaciclovir Zoster Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.1.76"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/095632029100200306"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.12.2417"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02116525"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.1.51"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1546"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706446"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/591390"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0150.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.12.1807"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1802"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1629-1636.2001"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/651078"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.6.1370"},{"key":"e_1_2_7_16_1","volume-title":"Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto)","author":"Soike KF","year":"1997"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.9.9.863"},{"key":"e_1_2_7_18_1","first-page":"20","volume-title":"Summary basis of approval (valtrex, herpes zoster)","author":"United States Food and Drug Administration (FDA)","year":"1995"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.822"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.23329","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.23329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:37:44Z","timestamp":1700570264000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.23329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,18]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1002\/jmv.23329"],"URL":"https:\/\/doi.org\/10.1002\/jmv.23329","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,18]]}}}